{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:26:42Z","timestamp":1785338802298,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40265-024-02003-w","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:41:07Z","timestamp":1709181667000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape"],"prefix":"10.1007","volume":"84","author":[{"given":"Seemal R.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2003_CR1","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","volume":"25","author":"BE Elewski","year":"2011","unstructured":"Elewski BE, Draelos Z, Dr\u00e9no B, et al. Rosacea: global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25:188\u2013200. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03751.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2003_CR2","unstructured":"American Academy of Dermatology. Skin conditions by the numbers. https:\/\/www.aad.org\/media\/stats-numbers. Accessed 6 Mar 2023."},{"key":"2003_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/jdv.13748","volume":"31","author":"B Halioua","year":"2017","unstructured":"Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients with rosacea. J Eur Acad Dermatol Venereol. 2017;31:163\u20138. https:\/\/doi.org\/10.1111\/jdv.13748.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2003_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13555-015-0077-2","volume":"5","author":"T Dirschka","year":"2015","unstructured":"Dirschka T, Micali G, Papadopoulos L, Tan J, Layton A, Moore S. Perceptions on the psychological impact of facial erythema associated with rosacea: results of international survey. Dermatol Ther (Heidelb). 2015;5:117\u201327. https:\/\/doi.org\/10.1007\/s13555-015-0077-2.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"2003_CR5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","volume":"82","author":"D Thiboutot","year":"2020","unstructured":"Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82:1501\u201310. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.077.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR6","first-page":"1","volume":"91","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91:1\u20138.","journal-title":"Cutis"},{"key":"2003_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/bjd","volume":"182","author":"M Schaller","year":"2020","unstructured":"Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea Consensus 2019 panel. Br J Dermatol. 2020;182:1269\u201376. https:\/\/doi.org\/10.1111\/bjd.","journal-title":"Br J Dermatol"},{"key":"2003_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00402621","volume":"282","author":"H Akamatsu","year":"1990","unstructured":"Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282:449\u201354. https:\/\/doi.org\/10.1007\/BF00402621.","journal-title":"Arch Dermatol Res"},{"key":"2003_CR9","first-page":"271","volume":"70","author":"JQ Del Rosso","year":"2002","unstructured":"Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271\u20135.","journal-title":"Cutis"},{"key":"2003_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2133.1983.tb03972.x","volume":"108","author":"PG Nielsen","year":"1983","unstructured":"Nielsen PG. Treatment of rosacea with 1% metronidazole cream: a double-blind study. Br J Dermatol. 1983;108:327\u201332. https:\/\/doi.org\/10.1111\/j.1365-2133.1983.tb03972.x.","journal-title":"Br J Dermatol"},{"key":"2003_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/archderm.1987.01660290077020","volume":"123","author":"PA Bleicher","year":"1987","unstructured":"Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123:609\u201314.","journal-title":"Arch Dermatol"},{"key":"2003_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/archderm.134.6.679","volume":"134","author":"MV Dahl","year":"1998","unstructured":"Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679\u201383. https:\/\/doi.org\/10.1001\/archderm.134.6.679.","journal-title":"Arch Dermatol"},{"key":"2003_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1067\/mjd.2001.116219","volume":"45","author":"MV Dahl","year":"2001","unstructured":"Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45:723\u201330. https:\/\/doi.org\/10.1067\/mjd.2001.116219.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaad.2013.05.019","volume":"69","author":"AB Coda","year":"2013","unstructured":"Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69:570\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2013.05.019.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR15","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.3109\/09546639309082150","volume":"4","author":"AJ Carmichael","year":"1993","unstructured":"Carmichael AJ, Marks R, Graupe KA, et al. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat. 1993;4:S19-22. https:\/\/doi.org\/10.3109\/09546639309082150.","journal-title":"J Dermatol Treat"},{"key":"2003_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1067\/mjd.2003.308","volume":"48","author":"D Thiboutot","year":"2003","unstructured":"Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836\u201345. https:\/\/doi.org\/10.1067\/mjd.2003.308.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR17","first-page":"541","volume":"7","author":"DM Thiboutot","year":"2008","unstructured":"Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7:541\u20136.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR18","first-page":"54","volume":"96","author":"ZD Draelos","year":"2015","unstructured":"Draelos ZD, Elewski BE, Harper JC, et al. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis. 2015;96:54\u201361.","journal-title":"Cutis"},{"key":"2003_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","volume":"54","author":"AN Sapadin","year":"2006","unstructured":"Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.004.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/jid.2012.14","volume":"132","author":"KN Kanada","year":"2012","unstructured":"Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Investig Dermatol. 2012;132:1435\u201342. https:\/\/doi.org\/10.1038\/jid.2012.14.","journal-title":"J Investig Dermatol"},{"key":"2003_CR21","first-page":"664","volume":"8","author":"JQ Del Rosso","year":"2009","unstructured":"Del Rosso JQ. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8:664\u20138.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR22","first-page":"573","volume":"7","author":"JQ Del Rosso","year":"2008","unstructured":"Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:573\u20136.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","volume":"56","author":"JQ Del Rosso","year":"2007","unstructured":"Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad of Dermatol. 2007;56:791\u2013802. https:\/\/doi.org\/10.1016\/j.jaad.2006.11.021.","journal-title":"J Am Acad of Dermatol."},{"key":"2003_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15180","volume":"35","author":"JQ Del Rosso","year":"2022","unstructured":"Del Rosso JQ, Brantman S, Baldwin H. Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily. Dermatol Ther. 2022;35: e15180. https:\/\/doi.org\/10.1111\/dth.15180.","journal-title":"Dermatol Ther"},{"key":"2003_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/exd.12030","volume":"21","author":"C Casas","year":"2012","unstructured":"Casas C, Paul C, Lahfa M, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21:906\u201310. https:\/\/doi.org\/10.1111\/exd.12030.","journal-title":"Exp Dermatol"},{"key":"2003_CR26","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/jdv.14437","volume":"31","author":"M Schaller","year":"2017","unstructured":"Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017;31:1907\u201311. https:\/\/doi.org\/10.1111\/jdv.14437.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2003_CR27","first-page":"316","volume":"13","author":"L Stein Gold","year":"2014","unstructured":"Stein Gold L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13:316\u201323.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR28","first-page":"1380","volume":"13","author":"L Stein Gold","year":"2014","unstructured":"Stein Gold L, Kircik L, Fowler J, et al. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13:1380\u20136.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR29","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jaad.2020.01.043","volume":"82","author":"L Stein Gold","year":"2020","unstructured":"Stein Gold L, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82:1166\u201373. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.043.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR30","first-page":"44","volume":"13","author":"L Stein Gold","year":"2020","unstructured":"Stein Gold L, Del Rosso JQ, Kircik L, et al. Open-label extension study evaluating long-term safety and efficacy of FMX103 1.5% minocycline topical foam for the treatment of moderate-to-severe papulopustular rosacea. J Clin Aesthet Dermatol. 2020;13:44\u20139.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"5","key":"2003_CR31","first-page":"27","volume":"4","author":"LH Kircik","year":"2011","unstructured":"Kircik LH. Microsphere technology: hype or help? J Clin Aesthet Dermatol. 2011;4(5):27\u201331.","journal-title":"J Clin Aesthet Dermatol."},{"key":"2003_CR32","first-page":"685","volume":"13","author":"JJ Leyden","year":"2014","unstructured":"Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol. 2014;13:685\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"2003_CR33","first-page":"34","volume":"16","author":"ND Bhatia","year":"2023","unstructured":"Bhatia ND, Werschler WP, Baldwin H, et al. Efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from two phase III, randomized, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16(8):34\u201340.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"8","key":"2003_CR34","first-page":"27","volume":"16","author":"WP Werschler","year":"2023","unstructured":"Werschler WP, Sugarman J, Bhatia N, et al. Long-term efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from an extension of two phase III, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16(8):27\u201333.","journal-title":"J Clin Aesthet Dermatol."},{"key":"2003_CR35","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/s0190-9622(99)70085-x","volume":"40","author":"S Maddin","year":"1999","unstructured":"Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40:961\u20135. https:\/\/doi.org\/10.1016\/s0190-9622(99)70085-x.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR36","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","volume":"139","author":"BE Elewski","year":"2003","unstructured":"Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444\u201350. https:\/\/doi.org\/10.1001\/archderm.139.11.1444.","journal-title":"Arch Dermatol"},{"key":"2003_CR37","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.13408","volume":"172","author":"A Taieb","year":"2015","unstructured":"Taieb A, Ortonne JP, Ruzicka T, et al. Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172:1103\u201310. https:\/\/doi.org\/10.1111\/bjd.13408.","journal-title":"Br J Dermatol"},{"key":"2003_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/jdv.13537","volume":"30","author":"A Taieb","year":"2016","unstructured":"Taieb A, Khemis A, Ruzicka T, et al. Ivermectin Phase III study group. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30:829\u201336. https:\/\/doi.org\/10.1111\/jdv.13537.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2003_CR39","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1186\/s40064-016-2819-8","volume":"5","author":"K Siddiqui","year":"2016","unstructured":"Siddiqui K, Stein Gold L, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis. Springerplus. 2016;5:1151. https:\/\/doi.org\/10.1186\/s40064-016-2819-8.","journal-title":"Springerplus"},{"key":"2003_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bjd.17590","volume":"181","author":"EJ van Zuuren","year":"2019","unstructured":"van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181:65\u201379. https:\/\/doi.org\/10.1111\/bjd.17590.","journal-title":"Br J Dermatol"},{"key":"2003_CR41","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.jaad.2013.06.009","volume":"69","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical \u03b1-adrenergic receptor agonist therapy? J Am Acad Dermatol. 2013;69:S44-56. https:\/\/doi.org\/10.1016\/j.jaad.2013.06.009.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR42","first-page":"650","volume":"12","author":"J Fowler Jr","year":"2013","unstructured":"Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12:650\u20136.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR43","first-page":"56","volume":"13","author":"A Moore","year":"2014","unstructured":"Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13:56\u201361.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR44","first-page":"33","volume":"14","author":"EA Tanghetti","year":"2015","unstructured":"Tanghetti EA, Jackson JM, Belasco KT, et al. Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol. 2015;14:33\u201340.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR45","first-page":"909","volume":"16","author":"L Stein Gold","year":"2017","unstructured":"Stein Gold L, Papp K, Lynde C, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16:909\u201316.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR46","first-page":"97","volume":"17","author":"LH Kircik","year":"2018","unstructured":"Kircik LH, DuBois J, Draelos ZD, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol. 2018;17:97\u2013105.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR47","first-page":"290","volume":"17","author":"L Baumann","year":"2018","unstructured":"Baumann L, Goldberg DJ, Stein Gold L, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second REVEAL trial. J Drugs Dermatol. 2018;17:290\u20138.","journal-title":"J Drugs Dermatol"},{"key":"2003_CR48","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaad.2018.01.027","volume":"78","author":"ZD Draelos","year":"2018","unstructured":"Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78:1156\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.027.","journal-title":"J Am Acad Dermatol"},{"key":"2003_CR49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-4632.2004.02283.x","volume":"43","author":"D Breneman","year":"2004","unstructured":"Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide\/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381\u20137. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02283.x.","journal-title":"Int J Dermatol"},{"key":"2003_CR50","first-page":"113","volume":"10","author":"T Williamson","year":"2017","unstructured":"Williamson T, Kamalakar R, Ogbonnaya A, Zagadailov EA, Eaddy M, Kreilick C. Rate of adverse events and healthcare costs associated with the topical treatment of rosacea. Am Health Drug Benefits. 2017;10:113\u20139.","journal-title":"Am Health Drug Benefits"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02003-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02003-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02003-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T18:07:29Z","timestamp":1711908449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02003-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2003"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02003-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"22 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing and editorial support for the preparation of this manuscript was provided by Simpson Healthcare and funded by Galderma Laboratories. The sponsor of the open access fee is Galderma Laboratories.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare the following potential conflicts. S.R.D. serves as a consultant for Galderma. In addition, he serves in multiple other leadership and industry roles unrelated to this product. H.B. has served as an advisor and speaker for Galderma, Bausch, Sun, Almirall, and EPI, as well as an advisor and investigator to Sol-Gel Technologies Ltd. J.Q.D.R. is a consultant, researcher, and speaker for Galderma, Almirall, Bausch Health (Ortho), Beiersdorf, BioPharmX, Cassiopeia, EPI Health, Ferndale, Leo Pharma, LaRoche-Posay, L\u2019Oreal, Main Pharma, SolGel, Sun Pharma, and Vyne. R.L.G. is a cofounder, scientific advisor, and consultant, has equity in MatriSys Biosciences, and is a consultant for Galderma. N.B. is a consultant for Abbvie, Almirall, Arcutis, Beiersdorf, Biofrontera, BMS, BI, Cara, Dermavant, EPI Health, Ferndale, Galderma, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Ortho, Pfizer, Regeneron, Sanofi, SunPharma, and Verrica. J.C.H. has served as consultant for Cutera, Almirall, Sun, LaRoche-Posay, Ortho, EPI, BioPharmX, Cassiopeia, Cutanea, Vyne, Galderma, Dermira and Sol-Gel Technologies Ltd.; a speaker for Almirall, Ortho, EPI, Vyne, and Galderma; and an advisory board member for EPI, Cassiopeia, Cutanea, Vyne, and Galderma. J.P.Y. is an employee of Galderma Laboratories. L.S.G. is an advisor\/investigator and\/or consultant for Galderma, Ortho Derm, EPI Health, Vyne, Novartis, Sun, and Cutera.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors assisted in the drafting of and critical revision of this manuscript. They have all read and approved the final version of the manuscript as well.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}